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Glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) is a member of the cysteine-
rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins (CAP)
superfamily.
1 Early studies showed that GLIPR1 was associated with myelomo-
nocytic differentiation toward the macrophage phenotype.
2 GLIPR1 was later
identified as a p53 target gene and was shown to be methylated and down-regulated
in prostate cancer.
3,4 Functional analysis of GLIPR1 using in vitro and in vivo gene-
transfer approaches revealed both growth suppression and proapoptotic activities
for mouse Glipr1 and human GLIPR1 in multiple cancer cell lines.
3-6 The proa-
poptotic activities were shown to depend on production of reactive oxygen species
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After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the
expression of GLIPR1 was shown to be down-regulated in human prostate cancer,
owing in part to methylation in the regulatory region of this gene in prostate cancer
cells. Additional studies showed that GLIPR1/Glipr1 expression is induced by
DNA-damaging agents independent of p53.  Functional analysis of GLIPR1 using
in vitro and in vivo gene-transfer approaches revealed both growth suppression
and proapoptotic activities for mouse Glipr1 and human GLIPR1 in multiple cancer
cell lines. The proapoptotic activities were dependent on production of reactive
oxygen species and sustained c-Jun-NH2 kinase signaling. It was interesting that
adenoviral vector-mediated Glipr1 (AdGlipr1) transduction into prostate cancer
tissues using an immunocompetent orthotopic mouse model revealed additional
biologic activities consistent with tumor-suppressor functions. Significantly reduced
tumor-associated angiogenesis and direct suppression of endothelial-cell sprouting
activities were documented. In addition, AdGlipr1 strongly stimulated antitumor
immune responses that resulted in specific cytotoxic T-lymphocyte activities in
this model. Glipr1-related antitumor immunostimulatory activities were confirmed
and extended in subsequent studies. Administration of a novel Glipr1 gene-
modified tumor cell vaccine had significant antitumor activity in a mouse model
of recurrent prostate cancer.  In conclusion, restoration of GLIPR1 function in
prostate cancer cells through GLIPR1 gene-based or GLIPR protein-based deli-
very methods may provide a safe and effective approach for targeted therapy for a
range of malignancies. 
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INTRODUCTION(ROS) and sustained c-Jun-NH2 kinase (JNK) signaling.
5
Further study showed that mice with an inactivated Glipr1
gene had significantly shorter tumor-free survival times
than did either Glipr1
+/+ or Glipr1
+/- mice in both p53
+/+ and
p53
+/- genetic backgrounds owing to the development of a
unique array of malignancies.
5 It was interesting that adeno-
viral vector-mediated Glipr1 (AdGlipr1) transduction into
prostate cancer tissues using an immunocompetent orthoto-
pic mouse model revealed additional biologic activities
consistent with tumor-suppressor functions. Significantly
reduced tumor-associated angiogenesis and direct suppres-
sion of endothelial-cell sprouting activities were document-
ed.
6 In addition, AdGlipr1 strongly stimulated antitumor
immune responses that resulted in specific cytotoxic T-cell
(CTL) activities in this model. Glipr1-related antitumor im-
munostimulatory activities were confirmed and extended in
subsequent studies. Administration of a novel Glipr1 gene-
modified tumor cell vaccine had significant antitumor acti-
vity in a mouse model of recurrent prostate cancer.
7
These preclinical study and other results led to the ini-
tiation and completion of a clinical trial in which an adeno-
viral vector-mediated GLIPR1 neoadjuvant injection was
tested in men with high-risk prostate cancer preceding
radical prostatectomy.
8 Additional AdGLIPR1 clinical test-
ing and potential development of GLIPR1 protein-based
therapies are under consideration.
The CAP superfamily and GLIPR1 subfamily
The CAP superfamily was named after it was recognized
that considerable sequence similarity exists among the cys-
teine-rich secretory proteins (CRISPs), antigen 5, and patho-
genesis-related proteins.
1 CRISPs are highly enriched in
the male mammalian reproductive tract and in the venom-
secretory ducts of snakes, lizards, and other vertebrates.
9,10
The highly immunogenic antigen 5 proteins are abundant
in the venom-secretory ducts of stinging insects,
11 and the
pathogenesis-related 1 proteins are up-regulated in plants
after invasion by pathogens.
12 Speculation about the func-
tional relationships among these CAP proteins has led to
the idea that they may actually be isozymes with distinct
substrate specificity
13 and overlap between the plant and
human immune systems.
14
The GLIPR1 gene was initially identified as being up-
regulated within glioblastoma multiforme and astrocytoma
tissues and in glioma cell lines.
15 Shortly after publication
of that initial report, a subsequent study identified the same
gene in glioma cell lines and called it “related to testes-
specific, vespid, and pathogenesis protein 1 (RTVP-1)”.
16
We also identified Rtvp-1/Glipr1 in a differential-display
polymerase chain reaction (PCR) screen as a p53 target
gene.
3 Identification of GLIPR1/Glipr1 was followed by
identification and cloning of multiple isoforms of additional
GLIPR1 subfamily genes. Mammalian GLIPR1 proteins
are a multigene subfamily that consists of three genes in
most species and four genes in the mouse.
1 We previously
identified two human GLIPR1-like genes (GLIPR1L1 and
GLIPR1L2) and three mouse Glipr1-like genes (Glipr1l1,
Glipr1l2, and Glipr1l3) as members of the GLIPR1 subfa-
mily.
1,17 An important note is that human GLIPR1, GLIP-
R1L1, and GLIPR1L2 genes are closely clustered on human
chromosome 12q21 and mouse Glipr1, Glipr1l1, Glipr1l2,
and Glipr1l3 genes, onmouse chromosome 10D1.
17 In addi-
tion, we found that all three members of the human GLIPR1
cluster are direct p53 targets. It is also important that we
further identified and characterized multiple alternative
transcripts for GLIPR1L1 and GLIPR1L2.
17 The presence
of a putative signal peptide sequence and extracellular
protein signature motifs suggests that most of the GLIPR1-
cluster proteins are located on the surface of the cell mem-
brane or secreted. Many, but not all GLIPR1-cluster proteins
also contain a transmembrane domain, suggesting different
capacities for secretion.
17 These results indicate that import-
ant regulatory functions are encoded in the GLIPR1/Glipr1
subfamily proteins. 
GLIPR1 subfamily gene expression is also highly tissue
specific. For example, in somewhat limited studies, we
showed that GLIPR1 expression is relatively widespread,
whereas GLIPR1L1 expression is highly tissue specific,
with very high mRNA levels in the testes but only trace
amounts in the bladder and undetectable expression in the
prostate, kidney, lung, and bone marrow. GLIPR1L2, like
GLIPR1L1, is highly expressed in the testes, yet relatively
low but detectable levels of expression were documented
in the prostate, kidney, bladder, lung, and bone marrow.
17
GLIPR1/Glipr1 as a tumor-suppressor protein
Initial studies of GLIPR1 expression provided clear evi-
dence of the potential for tumor-suppressor activities. Quan-
titative reverse-transcriptase PCR and/or in situ hybridi-
zation analysis showed that GLIPR1 expression was lower
in primary prostate cancer cells than in normal prostatic
epithelium.
4 In addition, prostate cancer cells that were
metastatic to lymph nodes demonstrated much lower levels
of expression than did normal prostate epithelium or pro-
state cancer. Although GLIPR1 mRNA was predominantly
localized in prostatic epithelial cells (among which the
basal cells exhibited the strongest signal level), some
isolated stromal cells also showed moderate GLIPR1
mRNA levels. 
Further, immunostaining analysis of normal prostate,
primary prostate cancer, and metastatic prostate cancer
samples showed that GLIPR1 protein expression is signi-
ficantly lower in primary prostate cancer than in normal
prostatic epithelium; GLIPR1 protein levels are still lower,
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or even undetectable, in lymph node metastases.
4 The
same study also showed that the human GLIPR1 promoter
is extensively methylated in prostate cancer tissues relative
to its methylation in normal prostate and that such increased
methylation correlates with decreased levels of GLIPR1
expression. These data led to the proposal that GLIPR1 is a
tumor suppressor that undergoes epigenetic inactivation in
prostate cancer.
4
Gene-transfer approaches were initially used to demon-
strate activities consistent with tumor-suppressor functions
of GLIPR1/Glipr1. P53-dependent and -independent
proapoptotic activities were demonstrated as a result of
GLIPR1/Glipr1 overexpression in multiple prostate cancer
cells and various malignant cell lines.
3 It was of interest
that the proapoptotic effect was considerably less in
nontransformed mouse embryo fibroblasts than in malig-
nant cell lines. That same study also revealed that gamma
irradiation and doxorubicin induced substantial levels of
GLIPR1 mRNA in both the presence and absence of p53,
which is suggestive of p53-independent GLIPR1 tumor-
suppressor functions. Moreover, we found that deletion of
the GLIPR1/Glipr1 signal peptide significantly reduced the
proapoptotic effects of GLIPR1/Glipr1 in vitro, suggesting
that secreted and/or release or cleavage from the mem-
brane is important for its biologic functions.
3
These initial studies were extended in subsequent studies
that showed that GLIPR1 overexpression led to significant
suppression of colony growth and induction of apoptosis in
multiple cancer cell lines.
5 To test our tumor-suppressor
hypothesis in vivo, we generated mice with an inactivated
Glipr1 gene; these Glipr1
-/- mice had significantly shorter
tumor-free survival times than either Glipr1
+/+ or Glipr1
+/-
mice did in both p53
+/+ and p53
+/- genetic backgrounds.
5 An
interesting finding was that a wide spectrum of tumors de-
veloped in the Glipr1
-/- mice, including lung carcinomas and
plasma cytomas. It was also notable that the progressive
loss of Glipr1 in the p53
+/- genetic background resulted in
progressive reduction of p53 loss of heterozygosity. These
data supported previous in vitro data
3,4 and showed that
Glipr1 has independent tumor-suppressor activities under
these conditions.
GLIPR1-mediated proapoptotic signaling
As a member of the CAP family, GLIPR1 contains 11
cysteines that are somewhat concentrated at the carboxyl
terminal of the molecule.
17 Because cysteine residues within
polypeptides can play important roles in redox homeos-
tasis in mammalian cells,
18,19 we hypothesized that GLIPR1
overexpression affects cellular ROS generation. The
results of extensive analysis showed that GLIPR1 overex-
pression led to significantly increased ROS in various
tumor cell lines, including prostate cancer cells.
5 Additional
studies showed that sustained JNK signaling resulted from
GLIPR1-stimulated ROS production. Overall, increased
ROS generation is required for GLIPR1-mediated activation
of JNK and ultimately the induction of apoptosis in an
inducible bladder-cancer cell model in vitro.
5
These results provided mechanistic underpinning to the
notion that GLIPR1 is a novel broad-spectrum tumor sup-
pressor whose proapoptotic properties are exerted in part
through ROS-JNK signaling.
GLIPR1-mediated effects on the tumor 
microenvironment
As a secreted and/or membrane-bound proapoptotic tumor-
suppressor protein, GLIPR1 (and potentially other GLIPR1
subfamily proteins) may have unique properties. GLIPR1
contains both an amino-terminal signal peptide and a
transmembrane domain.
17 In addition, the results of our
previous studies showed that deletion of the GLIPR1/
Glipr1 signal peptide significantly reduced the proapop-
totic effects of GLIPR1/Glipr1 in vitro.
3 Thus, it is likely
that GLIPR1 is secreted and/or tethered onto the membranes
of cells that express substantial levels of GLIPR1. Mem-
brane-bound GLIPR1 may also undergo proteolytic clea-
vage, adding to the extracellular pool of GLIPR1. Although
it is speculative, this biologic scenario would involve a
pool of extracellular GLIPR1 with the potential for signifi-
cant autocrine and/or paracrine activities. 
To move beyond speculation, it will be necessary to
directly test GLIPR1 protein under various conditions
using relevant cell types that are present in the prostate
cancer microenvironment. However, the results of pre-
vious studies are consistent with GLIPR1-mediated, multi-
cell type-specific tumor-suppressor activities. We previ-
ously showed that AdGlipr1 treatment of orthotopic mouse
prostate cancer resulted in reduced microvessel density and
that AdGlipr1 also directly inhibited endothelial-cell sprout-
ing in a rat aortic-ring sprouting assay.
6 These data are
consistent with antiangiogenic activities of secreted and/or
membrane-bound GLIPR1/Glipr1 in vivo. In addition, the
results of previous studies have shown that increased
expression of Glipr1 is associated with macrophage differ-
entiation.
2 Both of these cell types are dominant, active
components of the tumor microenvironment.
20 In further
support of the notion that secreted or cleaved GLIPR1/
Glipr1, we have shown that a vaccine prepared with mouse
prostate cancer cells, which were transduced with Glipr1
and irradiated, significantly reduced orthotopic prostate
cancer “tumor take” and establishment of experimental
prostate cancer lung metastases.
7 Increased natural-killer
cell and CTL activities were documented in those studies,
suggesting direct systemic immunostimulatory activities.
Overall, these data suggest that prostate tumor cell-derivedTimothy C. Thompson
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secreted or cleaved GLIPR1/Glipr1 may both exert direct
proapoptotic antitumor effects and suppress tumorigenesis
and/or local tumor growth through antiangiogenic and
immunostimulatory effects within the prostate cancer
microenvironment. Further studies are required to confirm
this hypothesis.
GLIPR1 as a therapeutic agent
Elucidation of the unique tumor-suppressor properties of
GLIPR1/Glipr1 led to the notion that GLIPR1 treatment
may be effective for local and/or systemic control of prostate
cancer and, potentially, other malignancies. Our preclinical
studies, described above, showed that direct injection of
AdGlipr1 into prostate cancer tissues using an immuno-
competent orthotopic mouse model resulted in significant
tumor growth suppression and longer survival of tumor-
bearing animals.
6 Analysis of AdGlipr1-treated tissues
demonstrated increased prostate cancer cell apoptosis and
significantly reduced tumor-associated angiogenesis. In
addition, AdGlipr1-stimulated antitumor immune respon-
ses resulted in specific CTL activities in this model. Glipr1-
related antitumor immunostimulatory activities were con-
firmed and extended in subsequent studies. Administration
of a novel Glipr1 gene-modified tumor cell vaccine to mice
had significant antitumor activity in a preclinical model of
recurrent prostate cancer.
7
On the basis of the results of our basic and preclinical
studies, we completed a phase 1b clinical trial of in situ,
adenoviral vector-mediated, neoadjuvant, pre-radical
prostatectomy GLIPR1 gene therapy in patients with locally
advanced adenocarcinoma of the prostate (IND13033).
Preliminary analysis of the data revealed that intraprostatic
administration of AdGLIPR1 was safe in men with local-
ized high-risk prostate cancer before radical prostatectomy.
In addition, preliminary evidence of biologic antitumor,
systemic, and local activity was observed, suggesting a
role for further development in the perioperative setting.
8
Because the growth-arrest and proapoptotic effects of
GLIPR1 are likely mediated to a large extent through
autocrine and/or paracrine activities in prostate cancer, we
have undertaken the development of GLIPR1 protein-
based anticancer therapy. It is conceivable that GLIPR1
protein therapy would have important advantages compar-
ed with viral vector-based GLIPR1 delivery under specific
conditions. For example, GLIPR1 protein may be delivered
systemically and therefore be potentially effective against
metastatic disease.
We have identified and characterized GLIPR1/Glipr1 as a
secreted tumor-suppressor protein. GLIPR1/Glipr1 is a
member of the GLIPR1 subfamily that includes multiple
proteins with potentially unique but overlapping functions.
GLIPR1/Glipr1 is regulated by p53 yet demonstrates p53-
independent tumor-suppressor activities. GLIPR1/Glipr1
can suppress the growth of multiple tumor cells and has po-
tent proapoptotic activities both in vitro and in vivo. GLIPR1
overexpression stimulates proapoptotic activities through
sustained ROS-JNK signaling. Of note, GLIPR1/Glipr1 can
also suppress angiogenesis and possesses immunostimul-
atory properties in vivo. Thus, in addition to direct tumor
cell-specific growth arrest and proapoptotic activities, the
tumor-suppressor activities of GLIPR1/Glipr1 may involve
the tumor microenvironment. Identification of GLIPR1/
Glipr1 and GLIPR1 subfamily members provides an op-
portunity for development of GLIPR1-based gene and
protein therapies for prostate cancer and other malignancies.
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